Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders

J Neurol Sci. 2013 Jan 15;324(1-2):38-9. doi: 10.1016/j.jns.2012.09.024. Epub 2012 Oct 2.

Abstract

We evaluated the safety and efficacy of rituximab in seven Chinese patients with neuromyelitis optica (NMO) or neuromyelitis optica syndrome disorders (NMOSD) in a tertiary medical center in Hong Kong. After rituximab induction, five patients became relapse-free and two had 50% reduction of relapses over a median follow-up of 24 months. No further deterioration of functional status, measured by the Expanded Disability Status Scale, was observed in all patients. Infusions were well tolerated except in two patients who developed transient hypotension. Rituximab reduced clinical relapse and prevented neurological deterioration in a small cohort of Chinese patients with NMO or NMOSD.

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Murine-Derived / adverse effects
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use*
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Asian Continental Ancestry Group
  • Disability Evaluation
  • Female
  • Hong Kong
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Infusions, Intravenous
  • Magnetic Resonance Imaging
  • Male
  • Methylprednisolone / therapeutic use
  • Middle Aged
  • Neuromyelitis Optica / drug therapy*
  • Recurrence
  • Rituximab
  • Young Adult

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Immunoglobulins, Intravenous
  • Rituximab
  • Methylprednisolone